Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $17.63.

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Bank of America lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Cantor Fitzgerald lifted their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, Guggenheim lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total transaction of $98,762.50. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 30,401 shares of company stock worth $352,038. 2.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Xponance Inc. raised its stake in shares of Amicus Therapeutics by 5.3% during the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 936 shares in the last quarter. Hazlett Burt & Watson Inc. raised its stake in shares of Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares in the last quarter. Arizona State Retirement System raised its position in Amicus Therapeutics by 2.6% in the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after acquiring an additional 1,577 shares in the last quarter. American International Group Inc. raised its position in Amicus Therapeutics by 1.3% in the first quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after acquiring an additional 1,785 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 1,884 shares in the last quarter.

Amicus Therapeutics Stock Up 0.6 %

FOLD stock opened at $9.72 on Tuesday. Amicus Therapeutics has a twelve month low of $9.02 and a twelve month high of $14.57. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $2.90 billion, a P/E ratio of -28.59 and a beta of 0.68. The firm has a 50 day simple moving average of $10.80 and a 200-day simple moving average of $10.59.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.